Scientist Jan G. is shown working in Johnson & Johnson’s molecule library, which stores more than 1.7 million unique compounds. Our scientists can access this library to order compounds for R&D activities at Johnson & Johnson. Photo by Frederik Beyens.

2022
Health for Humanity Report

Learn more about our progress

Year in Brief
Highlights

See full Year in Brief

> 180 million

patients treated with a Janssen medicine
> 586,000

cumulative doses of SIRTURO (bedaquiline) treatments for multidrug-resistant tuberculosis shipped
36 %

ethnic/racial diversity in management positions within the U.S., achieving the Health for Humanity 2025 Goal
> 130,000

employees (92%) responded to Our Credo Survey, with an 87% favorability rate among participants—a testament to our values-driven culture
100 %

renewable electricity secured for our operations in Brazil starting in 2023 through a direct Power Purchase Agreement
$ 14.6 billion

invested in research and development across our businesses

See full Year in Brief

Messages From Our Leadership

We are guided by Our Credo, a set of values that inspires our more than 153,000 employees to put the needs and well-being of the people we serve first. For 80 years, it has motivated us to solve complex health challenges with a spirit of innovation.

Joaquin DuatoChairman of the Board and Chief Executive Officer

Read Message From Our Chairman and CEO
We have taken many opportunities to engage with the business to help guide ESG considerations in decision making across many aspects of the Company’s activities.

Anne M. MulcahyLead Director, Johnson & Johnson Board of Directors

Read Q&A With Our Lead Director